Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,180 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06717113 | A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma | recruiting | Early Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | terminated | Early Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 |
| clinicaltrials |
| NCT06999031 | A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 12 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02966730 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy | terminated | Early Phase 1 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT03295240 | The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | completed | Early Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT01184885 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | completed | Early Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04566978 | 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) | completed | Early Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05846880 | VitD3 Supplementation in Patients With Multiple Myeloma | recruiting | Early Phase 1 | 100 | Amany Keruakous, MD, MS.OTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT03311958 | Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | completed | Early Phase 1 | 15 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06791681 | A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma | recruiting | Early Phase 1 | 24 | Chunrui LiOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT04890236 | Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | completed | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT05838131 | Study of CT071 Injection in RRMM or PPCL | active not recruiting | Early Phase 1 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05302648 | To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM | active not recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06209606 | Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | recruiting | Early Phase 1 | 30 | OncotherapeuticsINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06732232 | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma | recruiting | Early Phase 1 | 12 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06716164 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06693973 | An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Early Phase 1 | 13 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03804424 | 64Cu-LLP2A for Imaging Multiple Myeloma | terminated | Early Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03244176 | Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study(AvR-CHOP) | unknown | Early Phase 1 | 28 | Austin HealthOTHER_GOV | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06407947 | Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma | recruiting | Early Phase 1 | 10 | Shanghai Changzheng HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05048732 | Imaging Apoptosis for Lymphoma Treatment Response | terminated | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06346912 | CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL | recruiting | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06379451 | An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma | unknown | Early Phase 1 | 9 | Changzhou No.2 People's HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT02981914 | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | completed | Early Phase 1 | 12 | University of ChicagoOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT05013437 | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma(AHCT) | withdrawn | Early Phase 1 | 0 | Koen van BesienOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03771157 | Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors | completed | Early Phase 1 | 33 | University of RochesterOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06298266 | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 15 | Guangdong Second Provincial General HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05840107 | Study of FasT CAR-T GC012F Injection NDMM Patients | unknown | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05643248 | To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects | completed | Early Phase 1 | 9 | Nanexa ABINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05673447 | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | unknown | Early Phase 1 | 12 | Changhai HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03591614 | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT03219047 | Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma | completed | Early Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05715606 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 5, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02640209 | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | terminated | Early Phase 1 | 20 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03371420 | PET Imaging of Subjects Using 124I-PU-AD | terminated | Early Phase 1 | 5 | Samus Therapeutics, Inc.INDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05655676 | 89Zr-labeled NY008 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | withdrawn | Early Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02851056 | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | completed | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02405078 | Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | completed | Early Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05478343 | Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05430945 | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 100 | Zhejiang UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05364177 | 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jun 6, 2025source: clinicaltrials